Product Pipeline
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Key Innovative Programs
- Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
- Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
- Braftovi® (encorafinib) + Mektovi® (binimetinib): BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
- Duchenne Muscular Dystrophy Gene Therapy
- fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
- giroctocogene fitelparvovec: Hemophilia Gene Therapy
- Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
- Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
- Prophylactic Vaccine: Clostridioides difficile Infection
- Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
- Talzenna® (talazoparib): Prostate Cancer
- Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
- Xeljanz® (tofacitinib): Ankylosing Spondylitis
- Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer
Pipeline Snapshot as of April 28, 2020
- Discovery Projects
- 27Phase 1
- 37Phase 2
- 21Phase 3
- 6Registration
- Total91
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st Line BRAF-mutant Colorectal Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st Line BRAF-mutant Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Merkel Cell Carcinoma (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) (BREAKTHROUGH - U.S)
Project advanced | Registration | Product Enhancement | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Erbitux®(cetuximab) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor | 2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
recifercept Therapeutic Area: Rare Diseases Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Soluable recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy | Achondroplasia (Biologic) | Phase 1 | New Molecular Entity | Biologic |
somatrogon (PF-06836922) Therapeutic Area: Rare Diseases Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Human Growth Hormone Agonist | Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) | Phase 3 | Product Enhancement | Biologic |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 | Alopecia Areata | Phase 2 | Product Enhancement | Small Molecule |
ritlecitinib (PF-06651600) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC | Alopecia Areata (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Ankylosing Spondylitis | Phase 3 | Product Enhancement | Small Molecule |
brepocitinib (PF-06700841) Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical TYK2/JAK1 | Atopic Dermatitis | Phase 2 | New Molecular Entity | Small Molecule |
PF-07038124 Therapeutic Area: Inflammation & Immunology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: Topical PDE4 Inhibitor | Atopic Dermatitis | Phase 1 | New Molecular Entity | Small Molecule |
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor | Atopic Dermatitis (BREAKTHROUGH) | Phase 3 | New Molecular Entity | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | BRAF-mutant Metastatic Melanoma (ORPHAN - U.S.) | Phase 2 | Product Enhancement | Small Molecule |
